The effect of rosuvastatin and atrovastatin on plasma lipoprotein-associated phospholipase A2 activity in patients with hypercholesterolemia

Objective To evaluate the effect of rosuvastatin and atorvastatin on plasma lipoprotein-associated phospholipase A2(Lp-PLA2)activity in patients with hypercholesterolemia.Methods This was a randomized,double-blind study.After a 4-week therapeutic lifestyle changes period,patients with hypercholesterolemia randomly received rosuvastatin(5mg/d),rosuvastatin (10 mg/d)and atorvastatin(10 mg/d)for 8 weeks.The levels of serum total cholesterol,triglyceride,low-density lipoprotein cholasterol(LDL-C),hish-density lipopretein cholesterol and plasma Lp-PLA2 activity were measured at basetine and active treatment 8 weeks later.Results Sixty patients with hypereholesterolemia were enrolled in the study.Groups were matched in accordance with the baseline characteristics.After statins therapy serum LDL-C decreased by 35%,41%and 36%;plasma Lp-PLA2 activity decreased by 15%,17%and 15%in rosuvastatin(5mg/d),rosuvastatin(10mg/d)and atorvastatin(10mg/d),respectively,The correlations between plasma Lp-PLA2 activity and the level of serum LDL-C(r=0.507,P=0.00)were observod.Condusion The levels of plasma Lp-PLA2 activity are reduced significantly after rosuvastatin and atorvastatin therapy for 8 weeks in patients with hypercholesterolemia.There is correlation between plasma Lp-PLA2 activity and serum LDL-C. Key words: Rosuvastatin;  Atorvastatin;  Hypereholesterolemia;  Lipeprotein-associated phospholipase A2